4-(4-methoxy-phenyl)-thiomorpholine | 110195-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 4-(4-methoxy-phenyl)-thiomorpholine
• 英文别名: 4-(4-Methoxy-phenyl)-thiomorpholin；4-(4-Methoxyphenyl)thiomorpholine
• CAS: 110195-98-7
• 化学式: C₁₁H₁₅NOS
• mdl: MFCD02103146
• 分子量: 209.312
• InChiKey: FLRIAGFBHZHKLT-UHFFFAOYSA-N

物化性质

• 熔点：
  76-77 °C
• 沸点：
  366.5±37.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  37.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N,N-二(2-氯乙基)-4-甲氧基苯胺 在 sodium sulfide 、 丙酮 作用下， 生成 4-(4-methoxy-phenyl)-thiomorpholine
  参考文献：
  名称：

  162.芳基-2-卤代烷基胺。第六部分 与某些有机硫化合物的反应

  摘要：

  DOI：

  10.1039/jr9500000815

文献信息

• Nickel-Catalyzed Amination of Aryl Thioethers: A Combined Synthetic and Mechanistic Study
  作者：Alessandro Bismuto、Tristan Delcaillau、Patrick Müller、Bill Morandi

  DOI：10.1021/acscatal.0c00393

  日期：2020.4.17

  and kinetically competent catalysts for this transformation. The fleeting transmetalation intermediate has been successfully synthesized through an alternative synthetic organometallic pathway at lower temperature, allowing for in situ NMR study of the C–N bond reductive elimination step. This study addresses key factors governing the mechanism of the nickel-catalyzed Buchwald–Hartwig amination process

  在本文中，我们报道了镍1,2,2-双（二环己基膦基）乙烷（dcype）配合物用于芳基硫醚的Buchwald-Hartwig催化胺化。该方案显示了在催化条件下可耐受的各种不同官能团的广泛适用性。广泛的有机金属和动力学研究支持这种转化的镍（0）-镍（II）途径，并揭示了氧化加成配合物是催化循环的静止状态。已证明所有分离出的中间体都是这种转化的催化和动力学催化剂。通过在较低的温度下通过另一种合成的有机金属途径，已经成功合成了短暂的重金属化中间体，从而可以对C–N键的还原消除步骤进行原位NMR研究。
• Aminoacetamide acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20060287287A1

  公开（公告）日：2006-12-21

  There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , R 4 , R 5 , R 25 , R 26 and R 27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基胍类化合物，符合以下化学式（Ik）或其立体异构体；或其药学上可接受的盐，其中R2、R3、R4、R5、R25、R26和R27如本文所定义，它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及对β-淀粉样蛋白产生相关的神经疾病的治疗有用的化合物，如阿尔茨海默氏病和其他受抗淀粉样活性影响的病症。
• [EN] COMPOUNDS FOR USE IN THE TREATMENT OF PLANTS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES PLANTES
  申请人：PENINSULA COLLEGE OF MEDICINE AND DENTISTRY UNIVERSITY OF EXETER

  公开号：WO2012042227A1

  公开（公告）日：2012-04-05

  The invention relates to use of a compound in a treatment of a plant to promote plant growth wherein the compound is a salt comprising an anion of formula (1): or a conjugate acid thereof, wherein: R1, R2, R3, R4 and R5 are each independently selected from H, halogen, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2- C10 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkenyl, optionally substituted C3-Ci0 cycloalkynyl, hydroxy, optionally substituted C1 -C10 alkoxy, amino, mono-(C1-C10 alkyl)amino and di-(C1-C10 alkyl)amino groups; and Y is a nitrogen containing heterocyclyl group having from 3 to 14 ring atoms, a nitrogen containing heteroaryl group having from 3 to 14 ring atoms, an optionally substituted mono-(C1-C10 alkyl)amino group, an optionally substituted di-(C1-C10 alkyl)amino group or an optionally substituted tri-(C1-C10 alkyl)amino group. The compounds can be used to prevent or reduce stomatal closure or to cause stomatal opening in a plant. The invention further provides compounds for use in a herbicidal treatment of a plant. New compounds and a method for their manufacture are also described.

  该发明涉及使用一种化合物来促进植物生长的治疗，其中该化合物是包含式为(1)的阴离子的盐，或其共轭酸，其中：R1、R2、R3、R4和R5各自独立地选择自H、卤素、可选择取代的C1-C10烷基、可选择取代的C2-C10烯基、可选择取代的C2-C10炔基、可选择取代的C3-C10环烷基、可选择取代的C3-C10环烯基、可选择取代的C3-C10环炔基、羟基、可选择取代的C1-C10烷氧基、氨基、单-(C1-C10烷基)氨基和二-(C1-C10烷基)氨基基团；Y是含氮杂环基团，其环中含有3至14个环原子，含氮杂芳基团，其环中含有3至14个环原子，可选择取代的单-(C1-C10烷基)氨基基团，可选择取代的二-(C1-C10烷基)氨基基团或可选择取代的三-(C1-C10烷基)氨基基团。这些化合物可用于预防或减少植物气孔关闭，或引起植物气孔开放。该发明还提供了用于植物除草处理的化合物。还描述了新的化合物及其制备方法。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Nakajima, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1946, vol. 66, p. Ausg. B, S. 40, 45
  作者：Nakajima

  DOI：——

  日期：——